

Out-license partner Kowa announces it obtained domestic manufacturing and marketing approval for GLA-ALPHA[®] combination ophthalmic solution (ripasudil hydrochloride hydrate and brimonidine tartrate) for the treatment of glaucoma and ocular hypertension

SUMMARY

* This is the world's first fixed combination eye drops containing the active ingredients GLANATEC[®] ophthalmic solution 0.4% (rho-kinase inhibitor ripasudil hydrochloride hydrate) and an Alpha-2 adrenergic receptor agonist (brimonidine tartrate). The pharmacological point of action differs from that of existing fixed combination eye drops, allowing the product to be used in combination with a variety of glaucoma and ocular hypertension treatments. The use of multiple drug combinations is becoming the standard of care for the treatment of glaucoma. We expect that this drug will improve adherence and contribute to the treatment of glaucoma patients.

Summary of Approval Details

Trade name	GLA-ALPHA [®] combination ophthalmic solution
Generic name	Ripasudil hydrochloride hydrate and brimonidine tartrate
Indication	For patients with inadequate response to other glaucoma treatments in the following diseases: glaucoma, ocular hypertension
Dosage	1 drop per application, twice daily

* DWTI does not expect to receive any milestone payment as a result of this approval, and there will be no impact on business performance for the fiscal year ending December 31, 2022. The Company expects to commence sales of the drug during FY2022, and once the drug is launched, DWTI will receive license fees from Kowa based on the out-license agreement.

News Flash



D. WESTERN THERAPEUTICS INSTITUTE

Focus Points:

Drug discovery bio-venture with strengths in the kinase inhibitor mechanism and treatments for ophthalmic diseases such as glaucoma and ocular hypertension.

Chris Schreiber CFA

Company Specialist

research@sessapartners.co.jp



This report was prepared by Sessa Partners on behalf of D. Western Therapeutics Institute, Inc. Please refer to the legal disclaimer at the end for details.

LEGAL DISCLAIMER

This report is intended to provide information about the subject company, and it is not intended to solicit or recommend investment. Although the data and information contained in this report have been determined to be reliable, we do not guarantee their authenticity or accuracy.

This report has been prepared by Sessa Partners on behalf of the concerned company for which it has received compensation. Officers and employees of Sessa Partners may be engaged in transactions such as trading in securities issued by the company, or they may have the possibility of doing so in the future. For this reason, the forecasts and information contained in this report may lack objectivity. Sessa Partners assumes no liability for any commercial loss based on use of this report. The copyright of this report belongs to Sessa Partners. Modification, manipulation, distribution or transmission of this report constitutes copyright infringement and is strictly prohibited.



Sessa Partners Inc.

5-3-18, Hiroo, Shibuya-ku, Tokyo
info@sessapartners.co.jp